Tumor growth inhibition was dependent upon SMARCA2 degradation and was not due to non-specific effects of the chemical scaffold, as VHL and SMARCA2/4 -binding defective analogs A857 and A858 were not efficacious (Supplementary Fig. 6). This evidence concerns the gene SMARCA2 and neoplasm.